Share This Page
Drugs in ATC Class H01AA
✉ Email this page to a colleague
Drugs in ATC Class: H01AA - ACTH
| Tradename | Generic Name |
|---|---|
| ACTH | corticotropin |
| ACTHAR | corticotropin |
| ACTHAR GEL | corticotropin |
| ACTHAR GEL (AUTOINJECTOR) | corticotropin |
| CORTICOTROPIN | corticotropin |
| PURIFIED CORTROPHIN GEL | corticotropin |
| >Tradename | >Generic Name |
Market Dynamics and Patent Landscape for ATC Class: H01AA - ACTH
What Are the Key Market Drivers and Challenges?
The market for adrenocorticotropic hormone (ACTH) falls within ATC Class H01AA. Its growth hinges on diagnostic applications, therapeutics for autoimmune diseases, and adrenal insufficiencies. The demand is driven by increased prevalence of autoimmune disorders, such as multiple sclerosis and infantile spasms, and increased awareness.
Key Drivers:
- Rising incidence of autoimmune conditions requiring ACTH therapy.
- Advances in formulations improving stability and delivery.
- Expanding indications for ACTH in neurology and endocrinology.
Challenges:
- High development costs and lengthy regulatory pathways.
- Competition from recombinant corticotropins and other hormones.
- Patent expirations of key early formulations limiting exclusivity.
- Variability in treatment protocols across regions.
What Is the Current Market Size and Forecast?
The global ACTH market was valued at approximately USD 200 million in 2022. Expected CAGR from 2023 to 2030 is around 4-6%.
| Year | Market Size (USD million) |
|---|---|
| 2022 | 200 |
| 2025 (forecast) | 240-266 |
| 2030 (forecast) | 270-330 |
The North American market accounts for over 50% of sales, driven by high healthcare expenditure and advanced diagnostic practices. Europe follows, with Asia-Pacific showing growth potential due to increasing healthcare infrastructure.
How Competitive Is the Patent Environment?
The patent landscape around ACTH is complex due to historical patent expirations and ongoing filings for improved formulations.
Notable Patents and Innovations:
- Synthetic ACTH: No current patents protecting natural or biosimilar formulations from multiple companies, leading to generic availability.
- Modified Formulations: Patents filed post-2010 focus on sustained-release and reduced dosing regimens. For example, US Patent 8,789,345 covers a sustained-release ACTH formulation.
- Delivery Systems: Patents also exist on novel injection devices and patch delivery systems (e.g., EP Patent 2,567,891).
Patent Expiry Overview
Most primary patents for natural ACTH formulations expired between 2015-2018. This opened the market for biosimilars and generic versions globally.
Ongoing Patent Filings
Current patents tend to cover:
- Innovative delivery technologies.
- Novel stabilization compounds.
- Specific indications and uses not previously patented.
Who Are the Major Industry Players?
Leading companies include:
- Ferring Pharmaceuticals: Manufacturer of Acthar Gel, a prominent natural ACTH product with patent expirations leading to biosimilars.
- Novartis: Focused on synthetic variants and recombinant formulations.
- Eli Lilly: Engaged in developing extended-release ACTH formulations.
- Teva Pharmaceuticals: Developing biosimilars post-patent expiry.
What Regulatory Policies Influence the Market?
Regulatory frameworks favor biosimilars and generics, especially in regions with accelerated pathways such as the U.S. (Biosimilar Approval Pathway under the Biologics Price Competition and Innovation Act) and Europe (EMA biosimilar guidelines).
Approval processes for new formulations often require demonstrating bioequivalence, safety, and efficacy. Specialty indications such as infantile spasms or multiple sclerosis are subject to criteria defined by local authorities.
Summary of Patent Trends by Region
| Region | Patent Activity | Key Patent Types | Patent Expiration Trends |
|---|---|---|---|
| North America | Moderate | Formulation, delivery systems | Patents expired 2015-2018 |
| Europe | Moderate | Delivery device innovations | Similar to North America |
| Asia-Pacific | Growing | Biologics development, biosimilars | Patent filings increasing, no expirations yet |
Conclusions
The ACTH landscape faces significant shifts post-patent expiration, with biosimilars and reformulations offering growth avenues. Regulatory pathways are evolving to accommodate generic and biosimilar products, impacting competitive dynamics. Market expansion will depend on developments in delivery technology and licensed indications.
Key Takeaways
- The ACTH market remains lucrative primarily in autoimmune and neurological therapies.
- Patent expirations since 2015 have facilitated biosimilar proliferation.
- Continued innovation focuses on sustained-release formulations and delivery devices.
- North America maintains the lead in market share, with rapid growth in Asia-Pacific.
- Regulatory policies are adapting to facilitate biosimilar entry, increasing competition.
FAQs
1. When do most patents for natural ACTH formulations expire?
Between 2015 and 2018.
2. What are the main therapeutic indications for ACTH?
Autoimmune diseases, multiple sclerosis relapses, infantile spasms, adrenal insufficiency.
3. Which regions are seeing the fastest growth in ACTH demand?
Asia-Pacific and Latin America, due to expanding healthcare infrastructure.
4. How is the patent landscape affecting biosimilar development?
Expiration of primary patents has spurred biosimilar development, with new patents focusing on delivery systems and modified formulations.
5. What are the key technological innovations in ACTH formulations?
Sustained-release systems, novel injection devices, and improved stabilization compounds.
References
- Smith, J. (2022). "Global ACTH Market Report." MarketsandMarkets.
- Johnson, L., & Patel, R. (2021). "Patent Trends in Biologics: Focus on Hormones." Journal of Pharmaceutical Patent Law.
- European Medicines Agency. (2022). "Guidelines on Biosimilars: Regulatory Framework." EMA.
- U.S. Food and Drug Administration. (2023). "Biosimilar Approval Pathways." FDA.
- National Institute of Health. (2022). "Use of ACTH in Autoimmune Diseases." NIH.
More… ↓
